



# ISHITA DRUGS & INDUSTRIES LTD.

**Corp. Off.:** 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.  
**Phone :** +91 7226995613/14/15 | +91 79 2646 8353, 4002 3839 | **Fax :** +91 79 26404961  
**Regd. Office & Factory :** 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.  
**E-mail :** [ishitadrugs@gmail.com](mailto:ishitadrugs@gmail.com) | [ishitadrugs@vsnl.net](mailto:ishitadrugs@vsnl.net) | **URL :** [www.ishitadrugs.com](http://www.ishitadrugs.com)

**Date: 13<sup>th</sup> August, 2019**

To,  
The Company Section  
The Bombay Stock Exchange  
Phiroz Jijibhoy Towers  
Dalal Street, Bombay- 400 001

**Security Code: 524400**

Dear Sir,

**Sub: Outcome of Board Meeting held on 13<sup>th</sup> August, 2019 pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015.**

This is to inform you that the Board of directors of the Company at its meeting held today on Tuesday, the 13<sup>th</sup> Day of August, 2019 have

1. Approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter ended on 30<sup>th</sup> June, 2019 pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015.

Hope the enclosed papers are in accordance with requirements. Please take the same on your records and oblige. Please do the needful.

Thanking You.

**For, Ishita Drugs & Industries Ltd.**

*N.S.*

**Authorised Signatory**



ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad - 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Unaudited Financial Results for the Quarter Ended June 30, 2019

Amount in Lacs except Per Share data

Particulars	Figures for 3 Months Ended		Figures for Preceding 3 Months Ended		Figures for Corresponding 3 Months in the previous Year Ended		Figures for the previous year Ended	
	Un-audited 30-Jun-19	Audited 31-Mar-19	Un-audited 30-Jun-18	Audited 31-Mar-19	Un-audited 30-Jun-18	Audited 31-Mar-19	Un-audited 30-Jun-18	Audited 31-Mar-19
<b>1 INCOME</b>								
Revenue from Operations	386.06	295.39	178.22	908.72				
Other Income	2.90	12.23	1.39	16.34				
	<b>388.96</b>	<b>307.62</b>	<b>179.61</b>	<b>925.06</b>				
		<b>Total Income</b>						
<b>2 EXPENSES</b>								
(a) Cost of Material Consumed	297.73	215.36	112.42	620.62				
(b) Purchase of Stock-in-Trade	2.90	6.36	0.00	6.36				
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-in-Trade	5.90	7.28	2.99	13.16				
(d) Employee Benefit Expense	26.74	28.35	20.06	95.55				
(e) Finance Cost	0.89	3.85	1.19	6.06				
(f) Depreciation, Depletion and Amortisation Expense	4.22	3.62	3.40	15.59				
(g) Other Expense	34.68	28.26	29.37	121.43				
		<b>Total Other Expenses</b>						
		34.68	28.26	121.43				
		<b>Total Expenses</b>						
		373.05	293.08	878.77				
3		<b>Total Profit before Exceptional Items and Tax</b>						
		15.92	14.54	46.29				
4	Exceptional Items	0.00	0.00	0.00				
5		<b>Total Profit before Tax</b>						
		15.92	14.54	46.29				
6	Tax Expense							
7	Current Tax	3.72	3.55	2.29	11.50			
8	Deferred Tax	0.00	(0.37)	0.00	(0.37)			
9		<b>Total Tax Expenses</b>						
		3.72	3.18	2.29	11.13			
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement		0.00	0.00	0.00			
11	<b>Net Profit Loss for the period from continuing operations</b>	<b>12.20</b>	<b>11.36</b>	<b>7.89</b>	<b>35.16</b>			

*Jaydevin R. Patel*



12	Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00
13	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00
14	Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00
15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00
16	<b>Total Profit / (Loss) for the period</b>	<b>12.20</b>	<b>11.36</b>	<b>7.89</b>	<b>35.16</b>	
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00
18	<b>Total Comprehensive Income for the Period</b>	<b>12.20</b>	<b>11.36</b>	<b>7.89</b>	<b>35.16</b>	
19	<b>Total profit or loss attributable to</b>					
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00
20	<b>Total comprehensive income for the period attributable to</b>					
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00
21	<b>Details of Equity Share Capital</b>					
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00
22	<b>Details of Debt Securities</b>					
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00
24	Debtenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00
25	<b>Earnings Per Share</b>					
	<b>Earnings Per Share for continuing operations</b>					
	Basic Earnings / (Loss) per share from continuing operations	0.41	0.38	0.26	1.18	
	Diluted Earnings / (Loss) per share from continuing operations	0.41	0.38	0.26	1.18	
	<b>Earnings Per Share for discontinued operations</b>					
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
	<b>Earnings per Equity Share</b>					
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.41	0.38	0.26	1.18	
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.41	0.38	0.26	1.18	
26	Debt Equity Ratio	0.00	0.00	0.00	0.00	0.00
27	Debt Service Coverage Ratio	0.00	0.00	0.00	0.00	0.00
28	Interest Service Coverage Ratio	0.00	0.00	0.00	0.00	0.00

*Asst. Manager*



**NOTES**

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 13, 2019
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter ended 30th June, 2019 are Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website [www.ishitadrugs.com](http://www.ishitadrugs.com) and also at [www.bseindia.com](http://www.bseindia.com).

For, ISHITA DRUGS AND INDUSTRIES LIMITED



*Jagdish Agrawal*

Place	Ahmedabad			JAGDISH AGRAWAL
Date	13-Aug-19			MANAGING DIRECTOR DIN: 01031687